Feature | September 19, 2014

New Study Finds Systemic Hypothermia Does Not Improve Outcomes for Heart Attack Patients

Results of VELOCITY trial reported at TCT 2014

September 19, 2014 — According to a new study, peritoneal hypothermia is feasible for patients who have suffered ST-segment elevation myocardial infarction (STEMI). However, the procedure was associated with an increased rate of adverse events without reducing infarct size. These findings were reported at the 26th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium earlier this week.

Rapid reperfusion is essential to improve survival after the onset of myocardial injury in STEMI patients, but a significant proportion of patients experience sizeable losses of ventricular function despite reperfusion. Induction of hypothermia as a means of reducing infarct size has been previously explored using multiple methods to establish rapid hypothermia. However, many methods of inducing hypotheremia are not fast enough to ensure adequate cooling before percutaneous coronary intervention (PCI). Peritoneal lavage has been used to rapidly facilitate hypothermia for decades and has a well-established safety profile for the diagnosis of blunt abdominal injury in patients with trauma and for the treatment of accidental hypothermia, end-stage renal disease and cancer.

VELOCITY was a multicenter randomized trial that sought to determine the feasibility, safety and efficacy of systemic hypothermia induced by peritoneal lavage in patients with STEMI prior to primary PCI. The primary safety endpoint was the 30-day rate of death, reinfarction, ischemia-driven target vessel revascularization, major bleeding, sepsis, pneumonia, peritonitis, severe arrhythmia or renal failure. The primary efficacy endpoint was infarct size assessed by cardiac magnetic resonance imaging (MRI) after 3-5 days.

A total of 54 patients were randomized at seven centers to the hypothermia group (n=28) and the control group (n=26). Hypothermia was successfully initiated in 96.3 percent of patients and the median temperature at first balloon inflation was 34.7 degrees Celsius, indicating rapid cooling had been accomplished. Median door-to-balloon times in the hypothermia and control groups were 62 and 47 minutes, respectively (p=0.007). Both groups underwent primary PCI using standard techniques and adjunct pharmacology as per local standard of care.

The primary composite safety endpoint occurred in six (21.4 percent) patients in the hypothermia group driven by three stent thrombosis events. No patients in the control group experienced stent thrombosis or any adverse events (p=0.02 for comparison). Infarct size (as a percentage of left ventricular mass) was 17.2 percent in the hypothermia group and 16.1 percent in the control group (p=0.54).

“The establishment of peritoneal hypothermia before primary PCI in patients with STEMI was feasible, but did not reduce infarct size,” said lead investigator Gregg W. Stone, M.D., professor of medicine at Columbia University College of Physicians and Surgeons and director of cardiovascular research and education at the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center.

“The time to achieve the goal temperature prolonged door-to-balloon time modestly, and the procedure was associated with adverse events including stent thrombosis. These findings have implications not only for the peritoneal approach to hypothermia, but also raise general questions about the utility of systemic hypothermia to reduce infarct size. A large scale, appropriately powered trial is clearly needed to determine whether the rapid induction of mild systemic hypothermia reduces infarct size and improves clinical outcomes in patients with STEMI undergoing primary PCI,” said Stone.

The VELOCITY trial was funded by a grant from Velomedix Inc. Stone reported serving as a consultant to Velomedix.

For more information: www.crf.org, www.tctconference.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Overlay Init